Alembic Pharma: Optimized R&D Spend to Drive EBITDA Margin Growth

💊

expects its EBITDA margins to improve in the coming quarters, backed by more efficient R&D spending. The company highlighted this outlook during a recent investor call, signaling a focus on profitability.